# Immunotherapy Sector Canonical URL: https://biopharmsignal.com/sector/immunotherapy Immunotherapy includes companies using the immune system to fight disease, especially cancer and autoimmune conditions. This can include checkpoint inhibitors, immune agonists, engineered immune cells, therapeutic vaccines, and other approaches that modify immune activity. Companies currently grouped under Immunotherapy: 70 ## Recent Sector News - 2026-07-20 10:59 EST — BMY — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company - 2026-07-16 12:31 EST — MRK — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck - 2026-07-15 12:31 EST — MRK — [KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy](https://biopharmsignal.com/news/MRK/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-ceac984b) — Source: Merck - 2026-07-15 12:31 EST — MRK — [Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026](https://biopharmsignal.com/news/MRK/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-f70a5c44) — Source: Merck - 2026-07-13 12:00 EST — TCMD — [Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients](https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64) — Source: Tactile Systems Technology, Inc. - 2026-07-13 10:59 EST — BMY — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company - 2026-07-10 19:01 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-7cdef535) — Source: Merck - 2026-07-10 10:06 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-bc1625e5) — Source: Merck - 2026-07-10 10:06 EST — MRK — [Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Merck.com](https://biopharmsignal.com/news/MRK/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and--4390af46) — Source: Merck - 2026-07-10 10:06 EST — MRK — [Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Merck.com](https://biopharmsignal.com/news/MRK/merck-to-hold-second-quarter-2026-sales-and-earnings-conference-call-aug-4-merck-44a90bf3) — Source: Merck - 2026-07-09 19:07 EST — MRK — [Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com](https://biopharmsignal.com/news/MRK/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-bb1d1ada) — Source: Merck - 2026-07-09 11:56 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-e15b5e64) — Source: Merck - 2026-07-09 11:56 EST — MRK — [U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease - Merck.com](https://biopharmsignal.com/news/MRK/u-s-fda-approves-an-additional-indication-for-capvaxive-pneumococcal-21-valent-c-0b81d0d3) — Source: Merck - 2026-07-09 11:56 EST — MRK — [Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Merck.com](https://biopharmsignal.com/news/MRK/merck-s-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atla-f40c0831) — Source: Merck - 2026-07-09 11:56 EST — MRK — [European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer - Merck.com](https://biopharmsignal.com/news/MRK/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedot-b45629ae) — Source: Merck - 2026-07-09 09:04 EST — NEXI — [NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes | NexImmune, Inc.](https://biopharmsignal.com/news/NEXI/neximmune-yale-and-jdrf-extend-research-partnership-for-type-1-diabetes-neximmun-d017f773) — Source: NexImmune - 2026-07-09 09:04 EST — NEXI — [NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.](https://biopharmsignal.com/news/NEXI/neximmune-announces-3-67-million-registered-direct-offering-priced-at-the-market-d5bb4c90) — Source: NexImmune - 2026-07-09 09:04 EST — NEXI — [NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.](https://biopharmsignal.com/news/NEXI/neximmune-announces-closing-of-3-67-million-registered-direct-offering-priced-at-b57a79dd) — Source: NexImmune - 2026-07-06 12:00 EST — LCTX — [Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3) — Source: Lineage Cell Therapeutics - 2026-06-30 23:56 EST — MESO — [Receives FDA BLA Filing Number and Requests Modular Review](https://biopharmsignal.com/news/MESO/receives-fda-bla-filing-number-and-requests-modular-review-03d96298) — Source: Mesoblast ## Companies - [ABBV](https://biopharmsignal.com/company/ABBV) — AbbVie Inc - [ACIU](https://biopharmsignal.com/company/ACIU) — AC Immune - [ADAP](https://biopharmsignal.com/company/ADAP) — Adaptimmune Therapeutics plc - [ACET](https://biopharmsignal.com/company/ACET) — Adicet Bio - [AIM](https://biopharmsignal.com/company/AIM) — AIM ImmunoTech - [ALLO](https://biopharmsignal.com/company/ALLO) — Allogene Therapeutics - [ALPN](https://biopharmsignal.com/company/ALPN) — Alpine Immune Sciences - [ALT](https://biopharmsignal.com/company/ALT) — Altimmune - [AMGN](https://biopharmsignal.com/company/AMGN) — Amgen Inc. - [ANAB](https://biopharmsignal.com/company/ANAB) — AnaptysBio, Inc. - [ARGS](https://biopharmsignal.com/company/ARGS) — Argos - [BCEL](https://biopharmsignal.com/company/BCEL) — Atreca - [AUTL](https://biopharmsignal.com/company/AUTL) — Autolus Therapeutics plc - [BMY](https://biopharmsignal.com/company/BMY) — BMYBristol-Myers Squibb Company - [BCLI](https://biopharmsignal.com/company/BCLI) — Brainstorm Cell Therapeutics Inc. - [CABA](https://biopharmsignal.com/company/CABA) — Cabaletta Bio - [CRGX](https://biopharmsignal.com/company/CRGX) — CARGO Therapeutics - [RNAC](https://biopharmsignal.com/company/RNAC) — Cartesian Therapeutics - [CVM](https://biopharmsignal.com/company/CVM) — Cel-Sci Corporation - [IPSC](https://biopharmsignal.com/company/IPSC) — Century Therapeutics - [CGEN](https://biopharmsignal.com/company/CGEN) — Compugen Ltd. - [CRSP](https://biopharmsignal.com/company/CRSP) — CRISPR Therapeutics - [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences - [GRCL](https://biopharmsignal.com/company/GRCL) — Gracell Biotechnologies - [IMAB](https://biopharmsignal.com/company/IMAB) — I-MABDR - [IMRX](https://biopharmsignal.com/company/IMRX) — Immuneering - [IMCR](https://biopharmsignal.com/company/IMCR) — Immunocore Holdings plc - [IMGN](https://biopharmsignal.com/company/IMGN) — ImmunoGen - [IMNM](https://biopharmsignal.com/company/IMNM) — Immunome - [IMVT](https://biopharmsignal.com/company/IMVT) — Immunovant - [IMMP](https://biopharmsignal.com/company/IMMP) — Immutep Limited - [TIL](https://biopharmsignal.com/company/TIL) — Instil Bio - [IOVA](https://biopharmsignal.com/company/IOVA) — Iovance Biotherapeutics, Inc. - [ITOS](https://biopharmsignal.com/company/ITOS) — iTeos Therapeutics - [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson - [KYTX](https://biopharmsignal.com/company/KYTX) — Kyverna Therapeutics - [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation - [LCTX](https://biopharmsignal.com/company/LCTX) — Lineage Cell Therapeutics - [LUMO](https://biopharmsignal.com/company/LUMO) — Lumos Pharma - [LYEL](https://biopharmsignal.com/company/LYEL) — Lyell Immunopharma - [MRK](https://biopharmsignal.com/company/MRK) — Merck - [MESO](https://biopharmsignal.com/company/MESO) — Mesoblast - [MLTX](https://biopharmsignal.com/company/MLTX) — MoonLake Immunotherapeutics - [MBIO](https://biopharmsignal.com/company/MBIO) — Mustang Bio - [NAUT](https://biopharmsignal.com/company/NAUT) — Nautilus Biotechnology - [NEXI](https://biopharmsignal.com/company/NEXI) — NexImmune - [NKTX](https://biopharmsignal.com/company/NKTX) — Nkarta - [NKGN](https://biopharmsignal.com/company/NKGN) — NKGen Biotech, Inc. - [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG - [OMED](https://biopharmsignal.com/company/OMED) — OncoMed Pharmaceuticals - [ONCR](https://biopharmsignal.com/company/ONCR) — Oncorus - [PMCB](https://biopharmsignal.com/company/PMCB) — PharmaCyte Biotech - [PSTV](https://biopharmsignal.com/company/PSTV) — PLUS THERAPEUTICS, Inc. - [PGEN](https://biopharmsignal.com/company/PGEN) — Precigen - [PROK](https://biopharmsignal.com/company/PROK) — ProKidney - [PPBT](https://biopharmsignal.com/company/PPBT) — Purple Biotech - [QNRX](https://biopharmsignal.com/company/QNRX) — Quoin - [RAPT](https://biopharmsignal.com/company/RAPT) — RAPT Therapeutics - [SNY](https://biopharmsignal.com/company/SNY) — Sanofi - [SELB](https://biopharmsignal.com/company/SELB) — Selecta - [SNSE](https://biopharmsignal.com/company/SNSE) — Sensei Biotherapeutics - [SGTX](https://biopharmsignal.com/company/SGTX) — Sigilon Therapeutics - [SQZ](https://biopharmsignal.com/company/SQZ) — SQZ Biotech - [TCMD](https://biopharmsignal.com/company/TCMD) — Tactile Systems Technology, Inc. - [TRML](https://biopharmsignal.com/company/TRML) — Talaris Therapeutics - [THAR](https://biopharmsignal.com/company/THAR) — Tharimmune - [VCEL](https://biopharmsignal.com/company/VCEL) — Vericel Corp - [HOWL](https://biopharmsignal.com/company/HOWL) — Werewolf Therapeutics - [XBIO](https://biopharmsignal.com/company/XBIO) — Xenetic - [XLO](https://biopharmsignal.com/company/XLO) — Xilio Therapeutics